Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2011
Randomized Controlled Trial Multicenter StudyRandomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
To evaluate the ability of tacrolimus to reduce the corticosteroid dose in patients with myasthenia gravis (MG) and the drug's safety in a double-blind, placebo-controlled, parallel group study. ⋯ NCT00309088. Name of the trial registry: FK506 Phase 3 STUDY: A STUDY for Steroid Non-Resistant MG Patients.
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2011
Clinical scores for the identification of stroke and transient ischaemic attack in the emergency department: a cross-sectional study.
To compare the sensitivity and specificity of bedside diagnostic stroke scales in patients with suspected stroke. ⋯ The simpler FAST scale could replace the more complex ROSIER for the initial assessment of patients with suspected acute stroke in the emergency department.
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2011
Epilepsy and the subsequent risk of cerebral tumour: record linkage retrospective cohort study.
Studies suggest that seizures may precede the detection of cerebral tumour by several years. Aim To quantify the risk of cerebral tumour after new onset seizures, with particular interest in long term risk. ⋯ Seizures may herald the development of cerebral tumour, remote in time as well as soon after onset, with implications for guidelines on continued surveillance of those with new onset seizures.
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2011
Influence of prior transient ischaemic attack on stroke prognosis.
To evaluate potential neuroprotection afforded by prior transient ischaemic attack (TIA) on functional and survival outcomes after ischaemic stroke. ⋯ Recent prestroke TIA was associated with better functional outcome and lower 1-month and 1-year mortality after stroke, suggesting a neuroprotective effect.
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2011
Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained.
To ascertain the frequency and geographical distribution of patients diagnosed with known genetic causes of Alzheimer's disease (AD) and inherited prion disease (IPD) in the UK 2001-2005. By comparison with frequencies predicted from published population studies, to estimate the proportion of patients with these conditions who are being accurately diagnosed. ⋯ It is likely that patients with EOAD and IPD are not being recognised and referred for testing. With the prospect of meaningful disease modifying therapeutics for these diseases, this study highlights an issue of relevance to neurologists and those planning for provision of National Health Services.